SPC365

Mapping Cardiovascular Risk: Findings From a Community Screening

Session: Sessão de Posters 16 - Mapeamento do risco: dos scores ao cálcio
Speaker: Ana Filipa Escórcio Silva

Congress: CPC 2026
Topic: J. Preventive Cardiology
Theme: 28. Risk Factors and Prevention
Subtheme: 28.1 Risk Factors and Prevention – Epidemiology
Session Type: Posters Eletrónicos
FP Number: ---
Authors: Filipa Escórcio Silva; Maria Isabel Mendonça; Gonçalo Abreu; Francisco Sousa; Matilde Ferreira; Graça Caires; Luís Freitas; Sónia Freitas; Maria João Oliveira; Ana Célia Sousa; António Drumond

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Introduction:</span></span></strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"> Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Understanding the prevalence of modifiable cardiovascular risk factors is essential to guide prevention strategies and optimize routine clinical practice.</span></span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Objectives:&nbsp;</span></span></strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">To assess the prevalence of major cardiovascular risk factors in a </span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Southern European</span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"> community-based sample and stratify cardiovascular risk using the SCORE2 algorithm.</span></span></span></span></span></p>

<p style="text-align:start"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Methods:&nbsp;</span></span></strong></span></span></span><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">This cross-sectional observational study included 267 participants obtained through convenience sampling conducted between May 19 and 24, 2025. </span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Individuals aged &ge;40 years and residing in the geographic area of the screening were eligible. A questionnaire collected information on age, sex, smoking habits, and history of cardiovascular disease. Weight, height, and blood pressure were assessed, and glucose and lipid profiles were measured using rapid point-of-care test kits. </span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Subsequently, through consultation of the patient&rsquo;s clinical record, we retrieved the most recent laboratory results related to each participant&rsquo;s metabolic profile. Additionally, we obtained information on prescriptions for lipid-lowering, antihypertensive, and antidiabetic medications from the national electronic prescribing platform. </span></span><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">For the present analysis, only participants younger than 69 years and without diabetes mellitus were included. Cardiovascular risk was calculated using the SCORE2 algorithm.</span></span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Results:</span></span></strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"> The sample had a mean age of 55.9 years (&plusmn;7.6) and consisted of 186 females (69.7%) and 81 males (30.3%). Overweight/obesity (64.4%), hypertension (59.9%), and dyslipidemia (55.8%) were the most prevalent risk factors. Among participants with hypertension, 33.1% were receiving antihypertensive medication, while 23.5% of those with dyslipidemia were on lipid-lowering therapy. Most participants were classified as having low (68.5%) or moderate (27.7%) cardiovascular risk. Significant associations were found between SCORE2 risk categories and sex (p &lt; 0.0001) and smoking status (p = 0.001). In contrast, hypertension, dyslipidemia, and overweight/obesity showed no statistically significant association with SCORE2 risk.</span></span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Conclusion:</span></span></strong><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"> This study highlights the high prevalence of traditional cardiovascular risk factors in this community sample. Within the SCORE2 framework, only male sex and smoking status were significantly associated with higher cardiovascular risk, emphasizing the need for targeted preventive strategies in these subgroups.</span></span></span></span></span></p>